The record
Written from the 1 report below. Nothing here is unsourced.
- US President Donald Trump has announced a phased tariff on imported generic medicines, effective August 1, 2026: zero per cent for two years, 100 per cent for the following year, and 200 per cent thereafter.
- The stated aim is to push companies to move generic pharmaceutical manufacturing to the United States.
- India, the largest exporter of generic drugs to the US, sent USD 9.7 billion in pharmaceuticals there in 2025, which was 38 per cent of its total global pharma exports.
- The policy could significantly affect Indian generic drug exporters, whose medicines are widely used for conditions like diabetes, hypertension and cancer.
What to watch next
- How Indian pharma exporters and the government respond ahead of the August 2026 start date
- Whether companies shift manufacturing to the US during the two-year zero-tariff window
- Progress of India-US bilateral trade negotiations, including India's request to drop a proposed 12.5% tariff
Coverage1
1 report
English national1
All filed from India
Named United States · India · Donald Trump
The 1 report is listed beside the record.
Ask this story
Answers cite the reports above, or say they can't.